A targeted heart medication, already approved for adults, has shown significant promise in reducing dangerous obstruction in adolescents with a severe inherited heart disease, according to new clinical trial results.
The study found that mavacamten markedly improved heart function in teens with obstructive hypertrophic cardiomyopathy (HCM). After 28 weeks, adolescents taking the drug experienced a substantial reduction in the pressure gradient measuring heart obstruction, with a drop of approximately 48.5 mm Hg. In contrast, participants receiving a placebo saw almost no change, at 0.5 mm Hg. The medication's safety profile in this young population was also favorable, with side effects similar to the placebo group.
Hypertrophic cardiomyopathy is the most common inherited heart disease, causing the heart muscle to thicken and stiffen, which can block blood flow. It leads to symptoms like shortness of breath and chest pain and carries risks of heart failure and sudden cardiac death. Adolescents often present with more severe disease. Mavacamten works as a precision medicine by directly targeting the excessive myosin activity that causes the dysfunctional heart muscle contractions in HCM.
Beyond easing the physical obstruction, the trial revealed a potentially more profound effect. Blood biomarkers that indicate heart stress and injury decreased in patients on mavacamten but increased in those on placebo. This suggests the drug may help the heart muscle heal and could alter the disease's progression, rather than merely managing symptoms. "These results are encouraging as they suggest the drug might help the heart heal, changing the patient's underlying biology over time instead of just relieving symptoms," said the study's lead author, Dr. Joseph Rossano.
Researchers now aim to confirm these findings in larger, longer-term studies, with an eye toward seeking regulatory approval for pediatric use. If approved, mavacamten would become the first targeted therapy specifically for children and teens with this condition, offering a transformative alternative to current treatments that are limited to symptom-managing drugs or invasive surgeries. The hope is that earlier intervention could prevent years of cumulative heart damage, fundamentally improving long-term outcomes for young patients.